Pacira BioSciences Inc (NASDAQ: PCRX) started the day on Wednesday, with a price decrease of -0.83% at $16.64, before settling in for the price of $16.78 at the close. Taking a more long-term approach, PCRX posted a 52-week range of $11.16-$35.95.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 15.46%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 10.10%. This publicly-traded company’s shares outstanding now amounts to $46.48 million, simultaneously with a float of $44.58 million. The organization now has a market capitalization sitting at $768.33 million. At the time of writing, stock’s 50-day Moving Average stood at $16.37, while the 200-day Moving Average is $22.55.
Pacira BioSciences Inc (PCRX) Ownership Facts and Figures
Now let’s turn our focus to how large-scale investors are working with this stock of the Drug Manufacturers – Specialty & Generic Industry. Pacira BioSciences Inc’s current insider ownership accounts for 3.46%, in contrast to 112.78% institutional ownership. According to the most recent insider trade that took place on Sep 13 ’24, this organization’s Chief Operating Officer sold 500 shares at the rate of 12.86, making the entire transaction reach 6,430 in total value, affecting insider ownership by 115,700.
Pacira BioSciences Inc (PCRX) Earnings and Revenue Records
Pacira BioSciences Inc’s EPS increase for this current 12-month fiscal period is 10.10% and is forecasted to reach 2.95 in the upcoming year.
Pacira BioSciences Inc (NASDAQ: PCRX) Trading Performance Indicators
Let’s observe the current performance indicators for Pacira BioSciences Inc (PCRX). It’s Quick Ratio in the last reported quarter now stands at 1.89. The Stock has managed to achieve an average true range (ATR) of 0.74. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 1.11. Similarly, its price to free cash flow for trailing twelve months is now 3.97.
In the same vein, PCRX’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -2.05, a figure that is expected to reach 0.78 in the next quarter, and analysts are predicting that it will be 2.95 at the market close of one year from today.
Technical Analysis of Pacira BioSciences Inc (PCRX)
If we take a close look at the recent performances of Pacira BioSciences Inc (NASDAQ: PCRX), its last 5-days Average volume was 0.48 million that shows plunge from its year to date volume of 0.85 million. During the previous 9 days, stock’s Stochastic %D was recorded 45.40% While, its Average True Range was 0.72.
Raw Stochastic average of Pacira BioSciences Inc (PCRX) in the period of the previous 100 days is set at 42.66%, which indicates a major rise in contrast to 27.35% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 30.93% that was lower than 111.99% volatility it exhibited in the past 100-days period.
